Rosehip powder

Rosehip is a small, tidy, internally consistent evidence base, and the most useful thing this entry can do is show what that looks like and why it is not the same as a strong one.

What the pooled analysis found

Three randomized placebo-controlled trials, 287 patients in total — 145 on rosehip hip powder and 142 on placebo — with a median trial duration of three months. Pain fell in rosehip's favour with an effect size of 0.37 (95% CI 0.13–0.60, p = 0.002). A patient allocated to rosehip was about twice as likely to respond to treatment (odds ratio 2.19, p = 0.0009), which the authors converted into a number needed to treat of six (95% CI 4–13).

The heterogeneity statistic came out at I² = 0%. The three trials were, in statistical terms, measuring the same thing and finding the same amount of it.

Where that consistency comes from

All three trials were supported by the same manufacturer. The meta-analysis says so plainly, which is to its credit and is the reason it can be said here.

Three trials from one commercial programme agreeing with each other is consistency within a programme — shared protocols, shared endpoints, shared outcome definitions, shared decisions about what to measure and when to stop. It is not the same as three independent groups converging, and an I² of 0% across such a set carries much less information than the same number across unrelated trials would.

The authors were explicit about what would settle it. Their conclusion asked for efficacy and safety to be evaluated with independent replication in a future large-scale, long-term trial.

The eighteen years since

That trial has not been run. Searching in August 2026 returns no independent, non-manufacturer-supported randomized trial of rosehip in osteoarthritis, no trial with a structural or imaging endpoint, and no trial of rosehip as a food rather than a standardized powder.

An absence that long is itself informative. A supplement with a positive meta-analysis, a plausible mechanism and a commercial market has had nearly two decades in which someone could have confirmed it, and nobody has.

What it is supposed to be doing

The proposed active constituents are galactolipids, principally GOPO, with anti-inflammatory activity attributed to them in the wider Rosa canina literature. Rosehip is also unusually dense in vitamin C, which is a different argument entirely — it belongs with the vitamin C entry and with the collagen-synthesis cofactor case, and conflating the two is how a galactolipid claim ends up borrowing credibility from an ascorbate one.

Practical notes

The trials used standardized hip powder at doses that differ between them, and the pooled analysis does not settle on one. Rosehip's vitamin C content is relevant to the oxalate considerations already recorded under vitamin C. No safety signal appeared in the pooled analysis, though the authors listed safety among the things still needing evaluation.

What would change this entry

One independent trial. That is the whole answer, it has been the whole answer since 2008, and the fact that it is still the whole answer is the reason this entry is worth reading.